VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Item

http://www.wikidata.org/entity/Q34613164

Q34613164

about

Current Trends of Renal Impairment in Multiple Myeloma The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Bortezomib in patients with renal impairment.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Bortezomib in multiple myeloma: systematic review and clinical considerations.Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012 A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis Current multiple myeloma treatment strategies with novel agents: a European perspective Multiple myeloma treatment strategies with novel agents in 2011: a European perspective Guidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Myeloma bone disease: pathogenesis, current treatments and future targets.Advances in multiple myeloma therapy during two past decades.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.Nuances in the Management of Older People With Multiple Myeloma.Management of Elderly Patients with Plasma Cell Myeloma.Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry.The treatment of multiple myeloma patients not eligible for asct.Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis.Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era.Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?

P2860

Q26740444-5E971845-EF8A-439D-BBA3-FF555C9F1BA8 Q26740446-36305A9E-5FE7-443C-866C-26C9B927F5B3 Q27002668-D24AD7DF-D395-46C8-8BC3-F94EFD610E0A Q30595175-81994CBC-BED1-4DE3-B024-FFB9D66C6E6F Q33396250-34634FC7-B7EE-4E62-A1A5-E1F9646F9537 Q33400871-5C096B7E-3A3E-4AB2-8BD1-D99A8E2908A4 Q33404570-6C969C38-AD07-4F39-906A-A6675669F494 Q33408056-4DF20725-5680-44FC-82C7-0D6A593BF0D1 Q33418712-70CEA14B-E09D-4CF2-AC54-4406E6B4D006 Q33442039-1F82517D-C188-4732-8134-01BBC3C0804B Q33558161-96C78AE8-C5CA-43A4-ADA8-220F5730A40A Q33864162-98B75C11-99B4-4149-B85A-21A1453F7AA2 Q33982728-A449B0B2-070F-4258-9A9E-5213F1E25381 Q34448964-7AE54593-B7EE-4468-A3E3-4A8B279A65B7 Q35063100-88369323-1DF0-4D2F-BBD2-6F445E42BD30 Q35244883-7E8EB762-8139-42A3-85F2-9960ACB4E3A0 Q36115636-FAE83E0A-F77E-461B-A409-18644972779C Q36196981-7ED4C046-855C-458B-AF83-AD0FDD274200 Q37057028-CBC04DFA-2062-402C-9B6F-6748606DFF0B Q37375516-C014941B-86AB-4151-BBA1-5F2C20B406DD Q37677935-71A23D49-3BB4-4FBB-B2F0-2845A4BC6445 Q37858327-5BA1C194-C7DB-4971-8C41-3DA875C4FCCA Q37875193-3B5C1E9B-BB02-418C-AA9E-3B5726C4FE36 Q37903590-D5C0E4ED-FCFC-4AE3-8FCF-78CE2D60676E Q37908155-C8044498-24E7-46E9-AFF7-1F714BA60053 Q37978343-932769E5-9708-470C-8407-287ADAFE4B16 Q37986358-CC17B42C-ADBC-4AFF-B75E-4E829E26BD1E Q38109235-7512B857-9909-4E9A-9531-5EDC53858010 Q38246241-DDD88AF1-21E9-4D74-AF9E-5FDBC6D51D06 Q38248293-730C82EF-EDC9-47A5-8D5F-36F0080EE2CB Q38555091-97589E22-CAEC-4B21-AF96-9E448BC3280F Q38686511-30F80D02-D9C8-4479-B039-8BF029E67FF4 Q38796491-01F06928-94CE-46B1-B776-E4095FF59E4E Q39001325-F3C05570-59B0-4FDE-B16D-F0A335336D39 Q39273146-88FE582F-7405-4C03-8114-A4F85DF517BF Q40279004-54B4B384-EA09-4F62-A83B-675BE6D99730 Q42044723-89513F9A-9AA0-4B85-B570-E9C9A1F1CA20 Q42051905-4DA7E7E8-FBCC-4FD8-8C46-A563ABA28297 Q42318234-764C9162-7CE1-463B-841E-2CF5C98D22C4 Q42551347-904C9CFA-FD15-4CD4-AFD8-A976ECBEF610

P2860

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Item

http://www.wikidata.org/entity/Q34613164

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu